Medlab Clinical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDC.AX research report →
Price Chart
About the company
Medlab Clinical Limited is an Australian biotechnology firm dedicated to the research, development, and initial commercialization of innovative pharmaceutical and nutraceutical products. Its pipeline features key drug candidates such as NanaBis, a buccal spray derived from cannabis oil extract, intended for use in oncology and pain management. Another significant candidate is NanoCBD, a buccal spray sourced from hemp oil extract, aimed at supporting mental well-being.
- CEO
- Sean Michael Hall
- IPO
- 2015
- Employees
- 14
- HQ
- Botany, NSW, AU
Get TickerSpark's AI analysis on MDC.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.07M
- P/E
- -7.10
- PEG
- -0.07
- P/S
- 1267.12
- P/B
- -17.71
- EV/EBITDA
- -7.02
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -18989.10%
- Net Margin
- -17913.57%
- ROE
- -993.60%
- ROIC
- 265.44%
Latest fiscal year · YoY change
- Revenue
- $11.89K-98.7%
- Gross Profit
- $11.89K-98.5%
- Op Income
- $-2,258,564
- Net Income
- $-2,130,640+68.6%
- EPS
- $-0.93+68.7%
- OCF Growth
- +97.0%
- FCF Growth
- +97.0%
- 52W High
- $6.60
- 52W Low
- $6.60
- 50D MA
- $6.60
- 200D MA
- $6.60
- Beta
- 0.93
- RSI (14)
- 36
- Avg Volume
- 0
No earnings-call transcripts are available for MDC.AX yet.
- Free Float
- 73.6%
- Shares Outstanding
- 2.28M
- Float Shares
- 1.68M
Our MDC.AX coverage
Recent articles, reports, and earnings notes.
No research on MDC.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDC.AX report →